Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood filtering shows promise for high lipoprotein(a) in dialysis patients

NCT ID NCT07390604

Disease control Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small completed study looked at a blood filtering procedure called double-filtration plasmapheresis (DFPP) in 5 kidney dialysis patients with very high levels of lipoprotein(a), a fatty substance linked to heart disease and blood clots. The goal was to see if DFPP could lower those levels and possibly reduce cardiovascular risk. The study measured Lp(a) before and after each session, but because it was a tiny case series without a comparison group, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Double-filtration plasmapheresis (DFPP)
What this could lead to
If this works, it could point toward a way to lower heart and clot risks in kidney dialysis patients with very high lipoprotein(a).
What could go wrong
This is a tiny case series (5 people) with no control group, so results may not apply to others. The procedure is invasive and not a long-term fix.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5 people

The number who actually took part.

Started

Jul 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

chronic Hemodialsisi patients

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic hemodialysis patients with elevated Lp(a) levels (\>200 nmol/L) and a history of cardiovascular disease and/or thromboembolic events who underwent DFPP sessions as part of their management Exclusion Criteria: * -Patients with progressive, active disease, presenting with severe general deterioration and a limited life expectancy * Patients presenting with hemodynamic instability * Patients presenting with acute kidney diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic renal failure syndrome dialysis disequilibrium syndrome end stage renal failure venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Double-filtration plasmapheresis End stage chronic renal failure Hemodialysis complication Lipoprotein(A) Lipoprotein-apheresis

Contacts and locations

Locations

  • CHR Metz-Thionville Hopital de Mercy

    Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.